Corrigendum to “First versus second-generation molecular profiling tests: How both can guide decision-making in early-stage hormone-receptor positive breast cancers?” [Cancer Treat. Rev. 135 (2025) 102909]

Cancer Treatment Reviews 2026 Open access

Read full text
Authors: Flora Nguyen Van Long, Brigitte Poirier, Christine Desbiens, Marjorie P. Perron, Claudie Paquet, Cathie Ouellet, Caroline Diorio, Julie Lemieux, Hermann Nabi
DOI: 10.1016/j.ctrv.2026.103088
Cited by: 1

Abstract

The authors regret that during the preparation of the figures for this manuscript, an inadvertent error was introduced in the legend of Figure 2, in which the terms postmenopausal and premenopausal were mistakenly reversed. This error does not affect the interpretation of the data or the conclusions presented in the manuscript. The figure has been revised to reflect the correct terminology.

Fields of Study & Subjects

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies PARP inhibition in cancer therapy

Publication details

Journal / source
Cancer Treatment Reviews
Publisher
Elsevier BV
Volume
143
Pages
103088–103088
Publication date
27 January 2026
Language
EN